A citation-based method for searching scientific literature

Walter Kolch. Nat Rev Mol Cell Biol 2005
Times Cited: 799







List of co-cited articles
521 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



The MEK/ERK cascade: from signaling specificity to diverse functions.
Yoav D Shaul, Rony Seger. Biochim Biophys Acta 2007
651
11


Targeting RAS-ERK signalling in cancer: promises and challenges.
Ahmed A Samatar, Poulikos I Poulikakos. Nat Rev Drug Discov 2014
689
10

ERK signalling: a master regulator of cell behaviour, life and fate.
Hugo Lavoie, Jessica Gagnon, Marc Therrien. Nat Rev Mol Cell Biol 2020
210
10



MAP kinase signalling pathways in cancer.
A S Dhillon, S Hagan, O Rath, W Kolch. Oncogene 2007
8

Pathological roles of MAPK signaling pathways in human diseases.
Eun Kyung Kim, Eui-Ju Choi. Biochim Biophys Acta 2010
8

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
8

RAS Proteins and Their Regulators in Human Disease.
Dhirendra K Simanshu, Dwight V Nissley, Frank McCormick. Cell 2017
769
8

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
7

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.
Matthew Holderfield, Marian M Deuker, Frank McCormick, Martin McMahon. Nat Rev Cancer 2014
514
7

Signal integration by JNK and p38 MAPK pathways in cancer development.
Erwin F Wagner, Angel R Nebreda. Nat Rev Cancer 2009
7


The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation.
Alexander Plotnikov, Eldar Zehorai, Shiri Procaccia, Rony Seger. Biochim Biophys Acta 2011
533
7

A compendium of ERK targets.
Evrim B Ünal, Florian Uhlitz, Nils Blüthgen. FEBS Lett 2017
79
8

Nuclear ERK: Mechanism of Translocation, Substrates, and Role in Cancer.
Galia Maik-Rachline, Avital Hacohen-Lev-Ran, Rony Seger. Int J Mol Sci 2019
81
8



Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation.
A V Khokhlatchev, B Canagarajah, J Wilsbacher, M Robinson, M Atkinson, E Goldsmith, M H Cobb. Cell 1998
563
6

The RASopathies.
Katherine A Rauen. Annu Rev Genomics Hum Genet 2013
478
5


Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy.
Feifei Liu, Xiaotong Yang, Meiyu Geng, Min Huang. Acta Pharm Sin B 2018
204
5

The nuclear translocation of ERK1/2 as an anticancer target.
Alexander Plotnikov, Karen Flores, Galia Maik-Rachline, Eldar Zehorai, Einat Kapri-Pardes, Denise A Berti, Tamar Hanoch, Michal J Besser, Rony Seger. Nat Commun 2015
75
6

A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.
Federica Catalanotti, Gloria Reyes, Veronika Jesenberger, Gergana Galabova-Kovacs, Ricardo de Matos Simoes, Oliviero Carugo, Manuela Baccarini. Nat Struct Mol Biol 2009
115
5

IQGAP1 is a scaffold for mitogen-activated protein kinase signaling.
Monideepa Roy, Zhigang Li, David B Sacks. Mol Cell Biol 2005
181
5



Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis.
Yu Sun, Wen-Zhou Liu, Tao Liu, Xu Feng, Nuo Yang, Hua-Fu Zhou. J Recept Signal Transduct Res 2015
845
5

The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.
Mylène Tajan, Romain Paccoud, Sophie Branka, Thomas Edouard, Armelle Yart. Endocr Rev 2018
103
5

Integrating signals from RTKs to ERK/MAPK.
M M McKay, D K Morrison. Oncogene 2007
426
5

The MAPK pathway across different malignancies: a new perspective.
Mauricio Burotto, Victoria L Chiou, Jung-Min Lee, Elise C Kohn. Cancer 2014
531
4

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Axel Hauschild, Jean-Jacques Grob, Lev V Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U Blank, Wilson H Miller, Eckhart Kaempgen,[...]. Lancet 2012
4






PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase.
E Formstecher, J W Ramos, M Fauquet, D A Calderwood, J C Hsieh, B Canton, X T Nguyen, J V Barnier, J Camonis, M H Ginsberg,[...]. Dev Cell 2001
257
4

MAPK signalling: ERK5 versus ERK1/2.
Satoko Nishimoto, Eisuke Nishida. EMBO Rep 2006
313
4

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
Christopher J Caunt, Matthew J Sale, Paul D Smith, Simon J Cook. Nat Rev Cancer 2015
352
4

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation.
Jer-Yen Yang, Cong S Zong, Weiya Xia, Hirohito Yamaguchi, Qingqing Ding, Xiaoming Xie, Jing-Yu Lang, Chien-Chen Lai, Chun-Ju Chang, Wei-Chien Huang,[...]. Nat Cell Biol 2008
511
4

KSR as a therapeutic target for Ras-dependent cancers.
Beth K Neilsen, Danielle E Frodyma, Robert E Lewis, Kurt W Fisher. Expert Opin Ther Targets 2017
20
20

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
James A McCubrey, Linda S Steelman, William H Chappell, Stephen L Abrams, Ellis W T Wong, Fumin Chang, Brian Lehmann, David M Terrian, Michele Milella, Agostino Tafuri,[...]. Biochim Biophys Acta 2007
4

Scaffold proteins: hubs for controlling the flow of cellular information.
Matthew C Good, Jesse G Zalatan, Wendell A Lim. Science 2011
561
4



Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
M Abdur Razzaque, Tsutomu Nishizawa, Yuta Komoike, Hisato Yagi, Michiko Furutani, Ryunosuke Amo, Mitsuhiro Kamisago, Kazuo Momma, Hiroshi Katayama, Masao Nakagawa,[...]. Nat Genet 2007
335
4

Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.
M Tartaglia, E L Mehler, R Goldberg, G Zampino, H G Brunner, H Kremer, I van der Burgt, A H Crosby, A Ion, S Jeffery,[...]. Nat Genet 2001
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.